Hugh Taylor, MD, discusses topic which will be presented at the 4th Annual International Congress on the Future of Women’s Health.
Contemporary OB/GYN:
Hi, I'm Celeste Krewson with Contemporary OB/GYN and I'm here with Dr. Taylor to discuss Physicians’ Education Resources’ 4th Congress. Would like to introduce yourself?
Hugh Taylor, MD:
Hi, thanks, Celeste. I’m Dr. Hugh Taylor. I'm professor and chair of Obstetrics and Gynecology at the Yale School of Medicine and here to talk about the 4th annual International Congress on the Future of Women's Health.
Contemporary OB/GYN:
Well, thank you for being here today. To get started, can you go a bit into detail on the topics that will be presented at the conference?
Taylor:
I think it's a pretty exciting agenda. We're really looking to the future of women's health and helping practitioners prepare for what's changing and what's coming up. We've got a lot of great topics, including new therapies for some of the most common diseases we treat, for example, gynecology, endometriosis, and fibroids. We'll talk about what's new in LGBT care, migraines, various infectious diseases, genetic screening, genetics are exploding a lot of new information there, autoimmune disease, osteoporosis, what's changing in the political landscape that may be influencing your practice.
Contemporary OB/GYN:
Those are all great topics. Why is the Congress being conducted or rather, why was it started in the first place?
Taylor:
Well, medicine is rapidly evolving, and we need evidence-based answers that will help guide our practice, we need access to some of our nation's experts who are going to give you the latest from the clinical research, the changes in certain society guidelines in a clear and concise form, that are easily adapted right into practice.
Contemporary OB/GYN:
And what are some key developments in women's health recently that you've observed?
Taylor:
Well, there are a lot of new changes that are coming along again, the laws in this country are changing. Treatment guidelines are changing. There are new drugs that are being developed for very common gynecologic diseases, including fibroids, endometriosis, menopause, and there are lots of new drugs for immune dysfunction that are out there all sorts of exciting develops in medicine that we need to stay abreast of.
Contemporary OB/GYN:
You’re definitely right there. And what are you hoping physicians and doctors will take away from the conference?
Taylor:
Well, I hope they'll feel confident that they've kept up on the latest developments in the field that they've had access to the nation's experts. And some of the most fun is the Q&A session. So, you can get clarity around any of these very risk changing paradigms and guidelines that are out there.
Contemporary OB/GYN:
That's all great. We're just about ready to wrap up, but is there anything you want to add first?
Taylor:
No, I just hope a lot of people attend the conference. Please attend. It's a great day you'll learn and importance is something that will expand your horizons, add things that aren't part of the normal OB/GYN curriculum. So, this conference is open to anybody practicing in the field of women's health, not just OB/GYN It's appropriate for anybody who takes care of patients in the women's health field. Hope you all join us.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More
Unraveling preeclampsia: Insights into heterogeneity and intravascular inflammation
April 22nd 2024A recent study delved into the intricate clusters of term preeclampsia, shedding light on its diverse manifestations and the pivotal role of intravascular inflammation, paving the way for improved classification and management strategies.
Read More